Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

Maximilian Merz; Lina Jansen; Felipe A Castro; Jens Hillengass; Hans Salwender; Katja Weisel; Christof Scheid; Sabine Luttmann; Katharina Emrich; Bernd Holleczek; Alexander Katalinic; Alice Nennecke; Christian Straka; Christian Langer; Monika Engelhardt; Hermann Einsele; Nicolaus Kröger; Dietrich Beelen; Peter Dreger; Hermann Brenner; Hartmut Goldschmidt; GEKID cancer survival working group; German National Registry for Stem Cell Transplants (DRST)

doi:10.1016/j.ejca.2016.04.004

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

Standard

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. / Merz, Maximilian; Jansen, Lina; Castro, Felipe A; Hillengass, Jens; Salwender, Hans; Weisel, Katja; Scheid, Christof; Luttmann, Sabine; Emrich, Katharina; Holleczek, Bernd; Katalinic, Alexander; Nennecke, Alice; Straka, Christian; Langer, Christian; Engelhardt, Monika; Einsele, Hermann; Kröger, Nicolaus; Beelen, Dietrich; Dreger, Peter; Brenner, Hermann; Goldschmidt, Hartmut; GEKID cancer survival working group; German National Registry for Stem Cell Transplants (DRST).

in: EUR J CANCER, Jahrgang 62, 07.2016, S. 1-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Merz, M, Jansen, L, Castro, FA, Hillengass, J, Salwender, H, Weisel, K, Scheid, C, Luttmann, S, Emrich, K, Holleczek, B, Katalinic, A, Nennecke, A, Straka, C, Langer, C, Engelhardt, M, Einsele, H, Kröger, N, Beelen, D, Dreger, P, Brenner, H, Goldschmidt, H, GEKID cancer survival working group & German National Registry for Stem Cell Transplants (DRST) 2016, 'Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation', EUR J CANCER, Jg. 62, S. 1-8. https://doi.org/10.1016/j.ejca.2016.04.004

APA

Merz, M., Jansen, L., Castro, F. A., Hillengass, J., Salwender, H., Weisel, K., Scheid, C., Luttmann, S., Emrich, K., Holleczek, B., Katalinic, A., Nennecke, A., Straka, C., Langer, C., Engelhardt, M., Einsele, H., Kröger, N., Beelen, D., Dreger, P., ... German National Registry for Stem Cell Transplants (DRST) (2016). Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. EUR J CANCER, 62, 1-8. https://doi.org/10.1016/j.ejca.2016.04.004

Vancouver

Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K et al. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. EUR J CANCER. 2016 Jul;62:1-8. https://doi.org/10.1016/j.ejca.2016.04.004

Bibtex

@article{5073975bc470476caaafb290fa003989,

title = "Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation",

abstract = "BACKGROUND: The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma.METHODS: We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries).RESULTS: Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011.CONCLUSION: We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.",

keywords = "Aged, Female, Germany, Humans, Male, Middle Aged, Multiple Myeloma, Retrospective Studies, Stem Cell Transplantation, Survival Analysis, Transplantation, Autologous, Journal Article",

author = "Maximilian Merz and Lina Jansen and Castro, {Felipe A} and Jens Hillengass and Hans Salwender and Katja Weisel and Christof Scheid and Sabine Luttmann and Katharina Emrich and Bernd Holleczek and Alexander Katalinic and Alice Nennecke and Christian Straka and Christian Langer and Monika Engelhardt and Hermann Einsele and Nicolaus Kr{\"o}ger and Dietrich Beelen and Peter Dreger and Hermann Brenner and Hartmut Goldschmidt and {GEKID cancer survival working group} and {German National Registry for Stem Cell Transplants (DRST)}",

year = "2016",

month = jul,

doi = "10.1016/j.ejca.2016.04.004",

language = "English",

volume = "62",

pages = "1--8",

journal = "EUR J CANCER",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

AU - Merz, Maximilian

AU - Jansen, Lina

AU - Castro, Felipe A

AU - Hillengass, Jens

AU - Salwender, Hans

AU - Weisel, Katja

AU - Scheid, Christof

AU - Luttmann, Sabine

AU - Emrich, Katharina

AU - Holleczek, Bernd

AU - Katalinic, Alexander

AU - Nennecke, Alice

AU - Straka, Christian

AU - Langer, Christian

AU - Engelhardt, Monika

AU - Einsele, Hermann

AU - Kröger, Nicolaus

AU - Beelen, Dietrich

AU - Dreger, Peter

AU - Brenner, Hermann

AU - Goldschmidt, Hartmut

AU - GEKID cancer survival working group

AU - German National Registry for Stem Cell Transplants (DRST)

PY - 2016/7

Y1 - 2016/7

N2 - BACKGROUND: The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma.METHODS: We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries).RESULTS: Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011.CONCLUSION: We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.

AB - BACKGROUND: The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma.METHODS: We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries).RESULTS: Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011.CONCLUSION: We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.

KW - Aged

KW - Female

KW - Germany

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Retrospective Studies

KW - Stem Cell Transplantation

KW - Survival Analysis

KW - Transplantation, Autologous

KW - Journal Article

U2 - 10.1016/j.ejca.2016.04.004

DO - 10.1016/j.ejca.2016.04.004

M3 - SCORING: Journal article

C2 - 27185572

VL - 62

SP - 1

EP - 8

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -